Transplant outcomes of DCD livers recovered with vs. without pre-mortem heparin administration.
Pre-mortem heparin administration during donation after circulatory death (DCD) organ recovery is thought to optimize liver perfusion. However, pre-mortem heparinization is not universally practiced in the US and limited data exist regarding its utility. US registry data was accessed between January 1, 2003 and March 10, 2017, and two cohorts were ascertained: (1) DCD donor livers recovered for transplantation (n=5,495) and (2) liver-only adult transplant recipients of DCD livers (n= 3754). Exclusions were donor unknown heparin status (n=40), positive donor Hepatitis B Surface Antigen (n=4) and Hepatitis C (n=120) serologies, and for the outcomes analysis, livers placed outside the United States (n=10). Discard rates and graft outcomes were examined from cohorts 1 and 2 respectively. Of 5,495 DCD livers recovered for transplant, 589 (10.7%) donors did not receive pre-mortem heparin (no-heparin) and the remaining 4,906 (89.3%) received heparin (heparin). Liver discard was similar between the no-heparin (30.6%) and heparin groups (30.8%)(p=0.90). Heparin status was not associated with liver discard on multivariate analysis (adjusted OR 0.97, 95% CI 0.80-1.18, p=0.76). The cumulative probability of overall graft survival was lower in the no-heparin group relative to the heparin group (p<0.05) and this finding persisted on multivariate analysis. No-heparin group transplants had an 18% higher hazards of overall graft failure compared to those that received heparin (adjusted HR 1.18, 95% CI 1.01-1.38, p< 0.05). Organ recovery heparin administration status was not associated with liver discard. Failure to pre-treat organ donors with pre-mortem heparin correlates with worse liver transplant graft survival compared to heparin-treated livers.